Ali Khodaparast
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ali Khodaparast has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Farshad Gharebakhshi
Department of Radiology, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Anna Ghorbani Doshantapeh
Department of Hematology-Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Ardeshir Matoofi
Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Delnia Heidari
Department of Radiography and Diagnostic Imaging, School of Health and Social Work, University of Hertfordshire, Hatfield, United Kingdom
1 shared publication - Fatemeh Vashahi Torfi
Student Research Committee, Faculty of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication - Golmis Abdolmohammadi
School of Medicine Army University of Medical Sciences (AJA University of Medical Sciences), Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 4 April 2024
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 13 (2) , e11668
Association between vitamin D and bladder neoplasm; a systematic review and meta-analysis
Introduction: Bladder neoplasm ranks as the second most prevalent reproductive system malignancy worldwide. On the other hand, the vitamin D as an anti-cancer agent has been a subject of long-standing speculation. Hence, the objective of this study is to explore the correlation between vitamin D and bladder neoplasm risk. Materials and Methods: This systematic review and meta-analysis were designed following the PRISMA checklist. Eligible studies were identified through searches on ProQuest, PubMed, Web of Science, Google Scholar, and Cochrane, with no time restrictions until November 18, 2023. Data analysis was conducted utilizing the STATA 14 software. Results: Serum vitamin D levels less than 50 nmol/L increased the risk of bladder neoplasm (OR: 1.33; 95% CI: 1.08, 1.64), muscle-invasive bladder cancer (MIBC) (OR: 2.73; 95% CI: 1.80, 4.14) and non-muscle invasive bladder cancer (NMIBC) (OR: 1.87 (95% CI: 1.39, 2.52)). However, the risk of bladder neoplasm in people whose serum vitamin D level was less than 50 nmol/L did not increase with age. Vitamin D serum levels greater than or equal to 50 nmol/L in people aged 40 to 49 (OR: 0.51; 95% CI: 0.27, 0.99) prevented bladder neoplasm, but no significant association was seen in people over 50 years old. In addition, there was no significant association between daily vitamin D intake and the risk of bladder neoplasm (OR: 1.13; 95% CI: 0.63, 2.06). Conclusion: The serum vitamin D less than 50 nmol/L was correlated with bladder cancer risk increasing, including MIBC and NMIBC. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023487519) and Research Registry (UIN: reviewregistry1754) Websites.
- 4 April 2024
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 13 (2) , e11668
Open AccessAssociation between vitamin D and bladder neoplasm; a systematic review and meta-analysis
Introduction: Bladder neoplasm ranks as the second most prevalent reproductive system malignancy worldwide. On the other hand, the vitamin D as an anti-cancer agent has been a subject of long-standing speculation. Hence, the objective of this study is to explore the correlation between vitamin D and bladder neoplasm risk. Materials and Methods: This systematic review and meta-analysis were designed following the PRISMA checklist. Eligible studies were identified through searches on ProQuest, PubMed, Web of Science, Google Scholar, and Cochrane, with no time restrictions until November 18, 2023. Data analysis was conducted utilizing the STATA 14 software. Results: Serum vitamin D levels less than 50 nmol/L increased the risk of bladder neoplasm (OR: 1.33; 95% CI: 1.08, 1.64), muscle-invasive bladder cancer (MIBC) (OR: 2.73; 95% CI: 1.80, 4.14) and non-muscle invasive bladder cancer (NMIBC) (OR: 1.87 (95% CI: 1.39, 2.52)). However, the risk of bladder neoplasm in people whose serum vitamin D level was less than 50 nmol/L did not increase with age. Vitamin D serum levels greater than or equal to 50 nmol/L in people aged 40 to 49 (OR: 0.51; 95% CI: 0.27, 0.99) prevented bladder neoplasm, but no significant association was seen in people over 50 years old. In addition, there was no significant association between daily vitamin D intake and the risk of bladder neoplasm (OR: 1.13; 95% CI: 0.63, 2.06). Conclusion: The serum vitamin D less than 50 nmol/L was correlated with bladder cancer risk increasing, including MIBC and NMIBC. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023487519) and Research Registry (UIN: reviewregistry1754) Websites.
- Open Access
- 31 August 2023
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 12 (4) , e32207
The effect of cinacalcet on hypercalcemia in kidney transplant patients with hyperparathyroidism: systematic review and meta-analysis
Introduction: Following renal transplantation, patients with end-stage renal disease develop parathyroid dysfunction and electrolyte abnormalities, including calcium and phosphate levels. However, cinacalcet is one of the most used medications for hypercalcemia. Therefore, the present systematic review and meta-analysis aimed to investigate the effect of cinacalcet administration on hypercalcemia in patients with renal transplantation. Materials and Methods: The online databases of Cochrane, Web of Science, Scopus, and PubMed were searched until April 2023 using validated keywords. Moreover, PRISMA was used for qualitatively evaluating the studies since the study protocol was registered on the PROSPERO website. In addition, data analysis was conducted using Stata version 14, and the significance level was set at 0.05. Results: The present meta-analysis included 26 studies (24 cohort studies and two randomized clinical trials) investigating 602 patients with renal transplantation and hyperparathyroidism. According to our findings, cinacalcet reduced the serum calcium (MD: -2.24, 95% CI: -2.82, -1.67), parathormone (SMD: -0.85, 95% CI: -1.15, -0.54), and alkaline phosphatase levels (SMD: -0.45, 95% CI: -0.91, -0.01). Moreover, 30-60 mg of cinacalcet per day effectively treated hypercalcemia (SMD: -2.77, 95% CI: -3.57, -1.98), while other doses were not significantly effective. Furthermore, the effect of cinacalcet was investigated in patients using the medication for less than six months (SMD: -2.55, 95% CI: -4.25, -0.86), 12-18 months (SMD: -2.60, 95% CI: -3.53, -1.67), and more than 24 months (SMD: -1.71, 95% CI: -2.54, -0.88). Finally, the effect of cinacalcet was the highest in the patients who were 60-64 years old compared to other age groups (SMD: -3.59, 95% CI: -5.14, -2.04). Conclusion: Cinacalcet could improve hypercalcemia and hyperparathyroidism in patients with renal transplantation. Moreover, the effect of cinacalcet had a direct and positive relationship with the patient’s age. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42023428620) and Research Registry (UIN: reviewregistry1667) website.
- 31 August 2023
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 12 (4) , e32207
Open AccessThe effect of cinacalcet on hypercalcemia in kidney transplant patients with hyperparathyroidism: systematic review and meta-analysis
Introduction: Following renal transplantation, patients with end-stage renal disease develop parathyroid dysfunction and electrolyte abnormalities, including calcium and phosphate levels. However, cinacalcet is one of the most used medications for hypercalcemia. Therefore, the present systematic review and meta-analysis aimed to investigate the effect of cinacalcet administration on hypercalcemia in patients with renal transplantation. Materials and Methods: The online databases of Cochrane, Web of Science, Scopus, and PubMed were searched until April 2023 using validated keywords. Moreover, PRISMA was used for qualitatively evaluating the studies since the study protocol was registered on the PROSPERO website. In addition, data analysis was conducted using Stata version 14, and the significance level was set at 0.05. Results: The present meta-analysis included 26 studies (24 cohort studies and two randomized clinical trials) investigating 602 patients with renal transplantation and hyperparathyroidism. According to our findings, cinacalcet reduced the serum calcium (MD: -2.24, 95% CI: -2.82, -1.67), parathormone (SMD: -0.85, 95% CI: -1.15, -0.54), and alkaline phosphatase levels (SMD: -0.45, 95% CI: -0.91, -0.01). Moreover, 30-60 mg of cinacalcet per day effectively treated hypercalcemia (SMD: -2.77, 95% CI: -3.57, -1.98), while other doses were not significantly effective. Furthermore, the effect of cinacalcet was investigated in patients using the medication for less than six months (SMD: -2.55, 95% CI: -4.25, -0.86), 12-18 months (SMD: -2.60, 95% CI: -3.53, -1.67), and more than 24 months (SMD: -1.71, 95% CI: -2.54, -0.88). Finally, the effect of cinacalcet was the highest in the patients who were 60-64 years old compared to other age groups (SMD: -3.59, 95% CI: -5.14, -2.04). Conclusion: Cinacalcet could improve hypercalcemia and hyperparathyroidism in patients with renal transplantation. Moreover, the effect of cinacalcet had a direct and positive relationship with the patient’s age. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42023428620) and Research Registry (UIN: reviewregistry1667) website.